{
  "ticker": "IMU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02962347",
  "id": "02962347",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250626",
  "time": "1022",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250626/pdf/06l45yv7stxg8t.pdf",
  "summary": "**Summary of Announcement (Extraordinary General Meeting Notice):**  \n\n- **Clinical Trial Updates:**  \n  - **azer-cel (CD19 allo CAR T):** 57% complete response rate; durability >14 months (ongoing). Pivotal Phase 2/3 trial expected CY2026 (pending FDA meeting late 2025).  \n  - **onCARlytics (CD19-expressing virus):** Phase 1 in solid cancers with Blinatumomab; encouraging results in bile tract cancer.  \n  - **CF33 (Oncolytic Virus):** Phase 1 underway for late-stage solid cancers.  \n\n- **Manufacturing/Business:**  \n  - **Out-Licensing:** azer-cel Phase 1b manufacturing outsourced to Kincell to reduce costs.  \n  - **Partnering:** Ongoing discussions for out-licensing opportunities.  \n\n- **Capital/Corporate:**  \n  - **Cost Control:** Headcount reductions and program prioritization underway.  \n\n**No material capital markets transaction details (e.g., raising, timetable) identified.**  \n\n*(Note: EGM notice primarily operational; no resolutions or voting items disclosed in extract.)*",
  "usage": {
    "prompt_tokens": 648,
    "completion_tokens": 246,
    "total_tokens": 894,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-26T00:48:45.941049"
}